| Cover | Jul. 24, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This Form 8-K/A Amendment No. 1 amends the Current Report on Form 8-K of Enzo Biochem, Inc. (the “Company”), filed on July 24, 2023, regarding our sale of certain assets and assignment of certain liabilities of the Company’s clinical laboratory business. The sole purpose of this amendment is to provide the pro forma financial information required by Item 9.01. |
| Document Period End Date | Jul. 24, 2023 |
| Entity File Number | 001-09974 |
| Entity Registrant Name | Enzo Biochem, Inc. |
| Entity Central Index Key | 0000316253 |
| Entity Tax Identification Number | 13-2866202 |
| Entity Incorporation, State or Country Code | NY |
| Entity Address, Address Line One | 81 Executive Blvd. Suite 3 |
| Entity Address, City or Town | Farmingdale |
| Entity Address, State or Province | NY |
| Entity Address, Postal Zip Code | 11735 |
| City Area Code | 212 |
| Local Phone Number | 583-0100 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.01 par value |
| Trading Symbol | ENZ |
| Security Exchange Name | NYSE |
| Entity Emerging Growth Company | false |
